Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ensysce Biosciences, Inc. (ENSC : NSDQ)

• Company Description    Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $0.53 Daily Weekly Monthly 20 Day Moving Average: 875,502 shares Shares Outstanding: 34.56 (millions) Market Capitalization: $18.20 (millions) Beta: 0.53 52 Week High: $17.12 52 Week Low: $0.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -50.32% -45.60% 12 Week -51.69% -45.70% Year To Date -88.80% -86.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7946 IVANHOE AVENUE SUITE 201 - LA JOLLA,CA 92037 USA ph: 858-263-4196 fax: - shannon@mzgroup.us http://www.ensysce.com

• General Corporate Information    Officers Lynn Kirkpatrick - President; Chief Executive Officer and Director Bob Gower - Chairman David Humphrey - Chief Financial Officer; Secretary and Treasurer Andrew Benton - Director William Chang - Director Peer Information Ensysce Biosciences, Inc. (CORR.) Ensysce Biosciences, Inc. (RSPI) Ensysce Biosciences, Inc. (CGXP) Ensysce Biosciences, Inc. (BGEN) Ensysce Biosciences, Inc. (GTBP) Ensysce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 293602108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 34.56 Most Recent Split Date: (:1) Beta: 0.53 Market Capitalization: $18.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 15.17 Price/Cash Flow: - Price / Sales: 4.69 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 55.56% Sales Growth vs. Year Ago Period: 140.24% vs. Previous Quarter: -63.12% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - -484,682.75 ROA 03/31/22 - -289.01 12/31/21 - -247.16 09/30/21 - -270.56 Current Ratio 03/31/22 - 1.32 12/31/21 - 0.95 09/30/21 - 1.27 Quick Ratio 03/31/22 - 1.32 12/31/21 - 0.95 09/30/21 - 1.27 Operating Margin 03/31/22 - -887.38 12/31/21 - -845.19 09/30/21 - -686.96 Net Margin 03/31/22 - -788.03 12/31/21 - -845.07 09/30/21 - -680.67 Pre-Tax Margin 03/31/22 - -751.42 12/31/21 - -825.43 09/30/21 - -691.08 Book Value 03/31/22 - 0.03 12/31/21 - -0.34 09/30/21 - -0.02 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 1.43 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - 58.82 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©